skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Liraglutide in the management of type 2 diabetes

Review

(2158) Views  (1166) Full article downloads

Authors: Estela Wajcberg, Amatur Amarah

Published Date October 2010 Volume 2010:4 Pages 279 - 290
DOI: http://dx.doi.org/10.2147/DDDT.S10180

Estela Wajcberg, Amatur Amarah
Premier Nephrology and Hypertension, Internal Medicine Department, Trinitas Regional Medical Center, Elizabeth, New Jersey, USA

Abstract: The pathophysiology of type 2 diabetes has been attributed to the classic triad of decreased insulin secretion, increased insulin resistance, and elevated hepatic glucose production. Research has shown additional mechanisms, including incretin deficiency or resistance in the gastrointestinal tract. Liraglutide is a modified form of human glucagon-like peptide-1. Liraglutide was obtained by substitution of lysine 34 for arginine near the NH2 terminus, and by addition of a C16 fatty acid at the e-amino group of lysine (at position 26) using a γ-glutamic acid spacer. Liraglutide has demonstrated glucose-dependent insulin secretion, improvements in β-cell function, deceleration of gastric emptying, and promotion of early satiety leading to weight loss. Liraglutide has the potential to acquire an important role, not only in the treatment of type 2 diabetes, but also in preservation of β-cell function, weight loss, and prevention of chronic diabetic complications.

Keywords: diabetes mellitus, incretin, glucagon-like peptide, insulin resistance






Readers of this article also read:

Beyond post-marketing research and MedWatch: Long-term studies of drug risks
Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes
Potential of liraglutide in the treatment of patients with type 2 diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Use of electronic medical records in oncology outcomes research
An audit of orthopedic operation notes: what are we missing?
Racial differences in diabetes-related psychosocial factors and glycemic control in patients with type 2 diabetes
Drug discovery and development for neglected diseases: the DNDi model
Liraglutide therapy beyond glycemic control: An observational study in Indian patients with type 2 diabetes in real world setting
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University